NEW ORLEANS, Sept. 08, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 27, 2017 to file lead plaintiff applications in a securities class action lawsuit against Vitamin Shoppe, Inc. (NYSE:VSI), if they purchased the Company’s shares between the expanded period of March 1, 2017 and August 8, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Get Help
Vitamin Shoppe investors should visit us at https://www.claimsfiler.com/cases/nasdaq-vsi or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Vitamin Shoppe and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 1, 2017, Vitamin Shoppe announced that it expected to deliver “[f]ully diluted earnings per share in the range of $1.95 - $2.20” during fiscal year 2017. Subsequently, on May 10, 2017, the Company slashed FY17 guidance by more than 45% and then on August 9, 2017, revealed it was taking a goodwill impairment charge of $168 million and as a result, a GAAP loss per share of $6.73 in 2Q17.
On this news, the price of Vitamin Shoppe’s shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.


SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 



